

To NASDAQ OMX Copenhagen A/S

Translation

Company release No 12/2009

Hørsholm
September 26, 2009

GRAZAX[®] approved as a disease modifying allergy treatment

Page 1/2

Authorities in 27 European countries have approved GRAZAX[®] as a disease modifying allergy treatment. GRAZAX[®] is now the only registered tablet treatment against grass pollen allergy with documented sustained effect after completion of treatment.

The approval and the extended marketing authorisation are based on the results of the first follow-up year in a long-term study (GT-08) with GRAZAX[®] published at the European allergy congress in June 2009. The results document that the significant improvement of the patients' eye and nose symptoms and quality of life is sustained after completion of the recommended treatment regimen.

The patients in the GT-08 study have adhered to the recommended three-year GRAZAX[®] treatment regimen and completed treatment in the autumn of 2007. The 2008 pollen season was thus the first follow-up year in which the patients did not receive active treatment with GRAZAX[®].

The results represent a major breakthrough, since ALK is the first company ever to document a sustained disease modifying effect of an allergy immunotherapy tablet (AIT). Patients cannot obtain such a sustained disease modifying effect with traditional symptom-relieving allergy medication such as antihistamines and/or nasal corticosteroids.

This announcement does not change ALK's financial outlook for 2009.

ALK-Abelló A/S

Jens Bager
President & CEO

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. Our mission is to improve quality of life for allergic people by developing pharmaceutical products that target the actual cause of allergy. ALK is the world leader in allergy vaccination (immunotherapy) – a unique treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. Allergy vaccination is traditionally administered as subcutaneous injections or sublingual droplets. Our aim is to extend the use of allergy vaccination by introducing convenient, tablet-based vaccines, thereby offering many more patients a causal allergy treatment. Following this strategy, the world's first tablet-based vaccine against grass pollen allergy, GRAZAX[®], was launched in Europe in 2007. ALK has entered into a strategic partnership regarding the tablet programme with Schering-Plough for North America. ALK has approximately 1,500 employees with subsidiaries, production facilities and distributors worldwide. The company is headquartered in Hørsholm, Denmark and listed on NASDAQ OMX Copenhagen A/S. 'ALK' is an abbreviation of 'Allergological Laboratory Copenhagen (København)'. Further information is available at www.alk-abello.com and www.GRAZAX.com.

For further information please contact:

Per Plotnikof, Head of Investor Relations, tel: +45 2261 2525